Polen Capital Management Reduces $107M in Zoetis Inc. ($ZTS)

Key Points

  • Polen Capital Management changed its Zoetis Inc. ($ZTS) stake by 24.1% last quarter, cutting to 4,223,076 shares worth $336.03 million.
  • Wall Street's consensus rating on $ZTS is Buy and an average price target of $124.59.
  • $ZTS last traded around $79.57.

Polen Capital Management reduced its position in Zoetis Inc. ($ZTS) by 24.1% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,223,076 shares of Zoetis Inc. after selling 1,339,593 shares during the quarter. Polen Capital Management's holdings in Zoetis Inc. were worth $336.03 million as of its most recent filing.

Zoetis Inc. ($ZTS) Stock

Last price$79.57
Market cap$33.36B
P/E ratio13.04
Forward P/E10.72
PEG ratio1.91
Beta0.74
52-week low$72.38
52-week high$166.77
50-day MA$97.48
200-day MA$122.24
Current ratio3.15
Quick ratio1.68
Debt-to-equity2.86

Zoetis Inc. Earnings

EPS (ttm)$6.10
Revenue (ttm)$9.53B
Revenue growth2.9%
Net margin28.0%
Return on equity67.7%
Next earningsAug 4, 2026

Zoetis Inc. Dividend

Annual dividend$2.12
Dividend yield266.00%
Payout ratio33.3%
Ex-dividend dateJul 20, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$124.59
High target$160.00
Low target$90.00
Analysts covering17

About Zoetis Inc.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

ExchangeNYSE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersParsippany, NJ
CEOMs. Kristin C. Peck
Employees14,500

See Also

This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.